C15:0 (Pentadecanoic Acid / Fatty15)
Research suggests C15:0 may support cellular membrane health and metabolic function as an essential odd-chain fatty acid.
Human Trials
2
102 participants
Risk Level
Monthly Cost
Based on typical 100mg daily dosing
Quick Facts
- Category
- Supplement
- Research Field
- Supplements
- Evidence Grade
- C+ – Early
- Risk Level
- Low
- Monthly Cost
- $30 – $60
- Human Trials
- 2
Research Velocity
Mechanism of Action
C15:0 appears to function as an essential fatty acid that integrates into cellular membranes, particularly improving membrane stability and fluidity. Studies suggest it activates PPAR-alpha and PPAR-gamma receptors, potentially supporting metabolic health and cellular energy production. Research indicates it may also help maintain healthy inflammatory responses and support mitochondrial function.
Overview
Pentadecanoic acid (C15:0) is an odd-chain saturated fatty acid that research suggests may function as an essential nutrient. Unlike most dietary fats, C15:0 appears to have unique biological properties, with studies indicating it can integrate into cellular membranes and activate specific metabolic pathways. Research suggests that C15:0 levels have declined in human populations over recent decades, potentially due to reduced consumption of whole-fat dairy products, which are a primary dietary source.
Preliminary human studies indicate that C15:0 supplementation may support various aspects of metabolic health, including glucose metabolism and inflammatory markers. Animal and cell culture research suggests broader potential benefits for cellular aging, membrane stability, and mitochondrial function. The compound appears to work through multiple mechanisms, including activation of PPAR receptors and improvement of cellular membrane composition, though more extensive human trials are needed to fully understand its therapeutic potential.
As a relatively new area of research, C15:0 supplementation represents an emerging approach to nutritional optimization. While early findings are promising, the evidence base remains limited compared to more established supplements. The safety profile appears favorable based on available data, with C15:0 being a naturally occurring fatty acid found in various foods, though long-term supplementation studies are still needed.
Known Interactions
- May enhance effects of diabetes medications due to potential glucose-lowering properties
- Could theoretically interact with anticoagulant medications due to membrane effects
- No significant drug interactions reported in available studies
Legal Status by Country
Your country (United States)
Available without prescription in:
Australia, Brazil, Canada, Germany, Israel, Japan, Mexico, Netherlands, South Korea, Switzerland, Turkey, UAE, United Kingdom, United States, China, Colombia, India, Panama, Russia, Thailand
📍 = your selected country · ✈️ = medical tourism destination · Always verify current local regulations before travel.
Key Research
- 2021
comprehensive review of C15:0 health benefits
- 2020A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease
mechanistic overview of odd-chain fatty acids
- 2022The Emerging Role of Pentadecanoic Acid (C15:0) in Human Health: A Narrative Review
recent narrative review of C15:0 research
- 2020Pentadecanoic acid (C15:0), an essential fatty acid, shares anti-diabetic properties with metformin
preclinical metabolic studies
Related Interventions
Acetyl-L-Carnitine (ALCAR)
Research suggests acetyl-L-carnitine may support mitochondrial function, cognitive performance, and cellular energy metabolism.
Alpha-Lipoic Acid
A potent antioxidant supplement that research indicates may improve insulin sensitivity and reduce oxidative stress.
Apigenin
Research suggests apigenin, a flavonoid found in chamomile and parsley, may support cellular longevity through multiple anti-aging pathways.
Ashwagandha (KSM-66)
Adaptogenic herb showing promise for stress reduction, cortisol management, and cognitive function in multiple human trials.
Last verified: 2026-03-19